Advertisement

Vaccines

  • Wim JiskootEmail author
  • Gideon F. A. Kersten
  • Enrico Mastrobattista
  • Bram Slütter
Chapter

Abstract

Since the introduction of smallpox vaccination more than two centuries ago, vaccines have been—and still are—instrumental in the prevention of infectious diseases. Nowadays vaccines form a heterogeneous group of pharmaceutical products that differ in several aspects from other biopharmaceuticals. In this chapter, after a brief introduction we first cover immunological principles that are important for vaccine design. Next, we give an overview of the different vaccine categories and current approaches to vaccine development, illustrated with representative examples. We also describe current trends in the field of vaccines against non-infectious diseases, such as therapeutic vaccines against cancer and other diseases. Moreover, routes of administration relevant to vaccination and pharmaceutical aspects of vaccines are briefly discussed.

Keywords

Adjuvant Antigen Formulation Immunogenicity Immunological principles Route of administration Vaccine categories 

References

  1. Ahi YS, Bangari DS, Mittal SK (2011) Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 11(4):307–320CrossRefGoogle Scholar
  2. Amorij JP, Kersten GF, Saluja V, Tonnis WF, Hinrichs WL, Slütter B, Bal SM, Bouwstra JA, Huckriede A, Jiskoot W (2012) Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release 161(2):363–376CrossRefGoogle Scholar
  3. Batista FD, Harwood NE (2009) The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9(1):15–27CrossRefGoogle Scholar
  4. Berings M, Karaaslan C, Altunbulakli C, Gevaert P, Akdis M, Bachert C, Akdis CA (2017) Advances and highlights in allergen immunotherapy: on the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol 140(5):1250–1267CrossRefGoogle Scholar
  5. Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, McElrath MJ, Huang Y, Tomaras GD, Group HIVVTNS (2017) Immunogenicity of a novel Clade B HIV-1 vaccine combination: results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. PLoS One 12(7):e0179597CrossRefGoogle Scholar
  6. Cohen KW, Frahm N (2017) Current views on the potential for development of a HIV vaccine. Expert Opin Biol Ther 17(3):295–303CrossRefGoogle Scholar
  7. Czerkinsky C, Holmgren J (2012) Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol 354:1–18PubMedGoogle Scholar
  8. Dansokho C, Ait Ahmed D, Aid S, Toly-Ndour C, Chaigneau T, Calle V, Cagnard N, Holzenberger M, Piaggio E, Aucouturier P, Dorothee G (2016) Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain 139(Pt 4):1237–1251CrossRefGoogle Scholar
  9. Delves PJ, Roitt IM (2011) Roitt’s essential immunology, 12th edn. Wiley, ChichesterGoogle Scholar
  10. Donnelly JJ, Wahren B, Liu MA (2005) DNA vaccines: progress and challenges. J Immunol 175(2):633–639CrossRefGoogle Scholar
  11. Francis JN, Larche M (2005) Peptide-based vaccination: where do we stand? Curr Opin Allergy Clin Immunol 5(6):537–543CrossRefGoogle Scholar
  12. Garcia L, Jidy MD, Garcia H, Rodriguez BL, Fernandez R, Ano G, Cedre B, Valmaseda T, Suzarte E, Ramirez M, Pino Y, Campos J, Menendez J, Valera R, Gonzalez D, Gonzalez I, Perez O, Serrano T, Lastre M, Miralles F, Del Campo J, Maestre JL, Perez JL, Talavera A, Perez A, Marrero K, Ledon T, Fando R (2005) The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 73(5):3018–3024CrossRefGoogle Scholar
  13. Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 109(36):14604–14609CrossRefGoogle Scholar
  14. Germanier R, Fuer E (1975) Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis 131(5):553–558CrossRefGoogle Scholar
  15. Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5(7):505–517PubMedGoogle Scholar
  16. Hogan NC, Taberner AJ, Jones LA, Hunter IW (2015) Needle-free delivery of macromolecules through the skin using controllable jet injectors. Expert Opin Drug Deliv 12(10):1637–1648CrossRefGoogle Scholar
  17. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11(4 Suppl):S45–S53CrossRefGoogle Scholar
  18. Hunter Z, McCarthy DP, Yap WT, Harp CT, Getts DR, Shea LD, Miller SD (2014) A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 8(3):2148–2160CrossRefGoogle Scholar
  19. Kawai T, Akira S (2009) The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 21(4):317–337CrossRefGoogle Scholar
  20. Kersten G, Hirschberg H (2004) Antigen delivery systems. Expert Rev Vaccines 3(4):453–462CrossRefGoogle Scholar
  21. Kis EE, Winter G, Myschik J (2012) Devices for intradermal vaccination. Vaccine 30(3):523–538CrossRefGoogle Scholar
  22. Kubler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mulbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A (2015) Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer 3:26CrossRefGoogle Scholar
  23. Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M (2017) PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Rev Vaccines 16(3):197–213CrossRefGoogle Scholar
  24. Mallet E, Belohradsky BH, Lagos R, Gothefors L, Camier P, Carriere JP, Kanra G, Hoffenbach A, Langue J, Undreiner F, Roussel F, Reinert P, Flodmark CE, Stojanov S, Liese J, Levine MM, Munoz A, Schodel F, Hessel L, Hexavalent Vaccine Trial Study G (2004) A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 22(11–12):1343–1357CrossRefGoogle Scholar
  25. Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8(5):351–360CrossRefGoogle Scholar
  26. Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH (2015) Therapeutic cancer vaccines. J Clin Invest 125(9):3401–3412CrossRefGoogle Scholar
  27. Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5(12):905–916CrossRefGoogle Scholar
  28. Njuguna IN, Ambler G, Reilly M, Ondondo B, Kanyugo M, Lohman-Payne B, Gichuhi C, Borthwick N, Black A, Mehedi SR, Sun J, Maleche-Obimbo E, Chohan B, John-Stewart GC, Jaoko W, Hanke T (2014) PedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi. Vaccine 32(44):5801–5808CrossRefGoogle Scholar
  29. Northrup L, Christopher MA, Sullivan BP, Berkland C (2016) Combining antigen and immunomodulators: emerging trends in antigen-specific immunotherapy for autoimmunity. Adv Drug Deliv Rev 98:86–98CrossRefGoogle Scholar
  30. Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince-Kazmerova Z, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Winblad B, Novak M (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 16(2):123–134CrossRefGoogle Scholar
  31. O’Connell RJ, Excler JL, Polonis VR, Ratto-Kim S, Cox J, Jagodzinski LL, Liu M, Wieczorek L, McNeil JG, El-Habib R, Michael NL, Gilliam BL, Paris R, VanCott TC, Tomaras GD, Birx DL, Robb ML, Kim JH (2016) Safety and immunogenicity of a randomized phase 1 prime-boost trial with ALVAC-HIV (vCP205) and oligomeric glycoprotein 160 from HIV-1 strains MN and LAI-2 adjuvanted in alum or polyphosphazene. J Infect Dis 213(12):1946–1954CrossRefGoogle Scholar
  32. O’Hagan DT (1990) Intestinal translocation of particulates — implications for drug and antigen delivery. Adv Drug Deliv Rev 5(3):265–285CrossRefGoogle Scholar
  33. Oomen CJ, Hoogerhout P, Kuipers B, Vidarsson G, van Alphen L, Gros P (2005) Crystal structure of an Anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design. J Mol Biol 351(5):1070–1080CrossRefGoogle Scholar
  34. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547(7662):217–221CrossRefGoogle Scholar
  35. Paradiso PR, Hogerman DA, Madore DV, Keyserling H, King J, Reisinger KS, Blatter MM, Rothstein E, Bernstein HH, Hackell J (1993) Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics 92(6):827–832PubMedGoogle Scholar
  36. Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ, Edwards NJ, Jin J, Labbe GM, Alanine DG, Siani L, Di Marco S, Roberts R, Green N, Berrie E, Ishizuka AS, Nielsen CM, Bardelli M, Partey FD, Ofori MF, Barfod L, Wambua J, Murungi LM, Osier FH, Biswas S, McCarthy JS, Minassian AM, Ashfield R, Viebig NK, Nugent FL, Douglas AD, Vekemans J, Wright GJ, Faust SN, Hill AV, Long CA, Lawrie AM, Draper SJ (2017) Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight 2(21):96381CrossRefGoogle Scholar
  37. Pulendran B, Ahmed R (2011) Immunological mechanisms of vaccination. Nat Immunol 12(6):509–517CrossRefGoogle Scholar
  38. Raz R, Koren R, Bass D (2001) Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults. Isr Med Assoc J 3(5):328–332PubMedGoogle Scholar
  39. RTS,S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386(9988):31–45Google Scholar
  40. Samuels S, Marijne Heeren A, Zijlmans H, Welters MJP, van den Berg JH, Philips D, Kvistborg P, Ehsan I, Scholl SME, Nuijen B, Schumacher TNM, van Beurden M, Jordanova ES, Haanen J, van der Burg SH, Kenter GG (2017) HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia. Cancer Immunol Immunother 66(9):1163–1173CrossRefGoogle Scholar
  41. Sebastian M, Papachristofilou A, Weiss C, Fruh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A (2014) Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 14:748CrossRefGoogle Scholar
  42. Shamji MH, Durham SR (2017) Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol 140(6):1485–1498CrossRefGoogle Scholar
  43. Slütter B, Jiskoot W (2016) Sizing the optimal dimensions of a vaccine delivery system: a particulate matter. Expert Opin Drug Deliv 13(2):167–170CrossRefGoogle Scholar
  44. Timmerman P, Puijk WC, Meloen RH (2007) Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology. J Mol Recognit 20(5):283–299CrossRefGoogle Scholar
  45. van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16(4):219–233CrossRefGoogle Scholar
  46. van der Maaden K, Jiskoot W, Bouwstra J (2012) Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release 161(2):645–655CrossRefGoogle Scholar
  47. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, van den Hende M, Lowik MJ, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Melief CJ, Kenter GG, van der Burg SH (2013) HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 11:88CrossRefGoogle Scholar
  48. Van Regenmortel MH (2009) What is a B-cell epitope? Methods. Mol Biol 524:3–20Google Scholar
  49. Vanlandschoot P, Roobrouck A, Van Houtte F, Leroux-Roels G (2002) Recombinant HBsAg, an apoptotic-like lipoprotein, interferes with the LPS-induced activation of ERK-1/2 and JNK-1/2 in monocytes. Biochem Biophys Res Commun 297(3):486–491CrossRefGoogle Scholar
  50. Vela Ramirez JE, Sharpe LA, Peppas NA (2017) Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev 114:116–131CrossRefGoogle Scholar
  51. Vreden SG, Verhave JP, Oettinger T, Sauerwein RW, Meuwissen JH (1991) Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am J Trop Med Hyg 45(5):533–538CrossRefGoogle Scholar
  52. Wong G, Mendoza EJ, Plummer FA, Gao GF, Kobinger GP, Qiu X (2018) From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opin Biol Ther 18(2):159–173CrossRefGoogle Scholar

Suggested Reading

  1. Abbas AK, Lichtman AH, Pillai S (2014) Basic immunology: functions and disorders of the immune system, 4th edn. Elsevier/Saunders, PhiladelphiaGoogle Scholar
  2. Delves PJ, Martin SJ, Burton DR, Roitt IM (2017) Roitt’s essential immunology, 13th edn. Wiley, HobokenGoogle Scholar
  3. Plotkin SA, Orenstein WA, Offit PA, Edwards KM (2017) Vaccines, 7th edn. Elsevier, CambridgeGoogle Scholar
  4. Pulendran B, Ahmed R (2011) Immunological mechanisms of vaccination. Nat Immunol 12(6):509–517CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Wim Jiskoot
    • 1
    Email author
  • Gideon F. A. Kersten
    • 2
  • Enrico Mastrobattista
    • 3
  • Bram Slütter
    • 1
  1. 1.Division of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR)Leiden UniversityLeidenThe Netherlands
  2. 2.Institute for Translational VaccinologyBilthovenThe Netherlands
  3. 3.Department of PharmaceuticsUtrecht UniversityUtrechtThe Netherlands

Personalised recommendations